Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer - Trial NCT06326736
Access comprehensive clinical trial information for NCT06326736 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jinling Hospital, China and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jinling Hospital, China
Timeline & Enrollment
Phase 1
Apr 01, 2024
Dec 01, 2026
Primary Outcome
Incidence of Treatment Emergent Adverse Events (TEAEs)
Summary
The purpose of this study is to evaluate the safety and efficacy of treating pancreatic
 cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized
 cancer mRNA vaccines.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06326736
Non-Device Trial